AR059984A1 - Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa -iv para el tratamiento o prevencion de diabetes - Google Patents
Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa -iv para el tratamiento o prevencion de diabetesInfo
- Publication number
- AR059984A1 AR059984A1 ARP070101127A ARP070101127A AR059984A1 AR 059984 A1 AR059984 A1 AR 059984A1 AR P070101127 A ARP070101127 A AR P070101127A AR P070101127 A ARP070101127 A AR P070101127A AR 059984 A1 AR059984 A1 AR 059984A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- alkoxy
- hydroxy
- substituents
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 17
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 16
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 15
- 125000001424 substituent group Chemical group 0.000 abstract 15
- 125000000217 alkyl group Chemical group 0.000 abstract 12
- 125000003545 alkoxy group Chemical group 0.000 abstract 11
- 229910052736 halogen Inorganic materials 0.000 abstract 9
- 229910052731 fluorine Inorganic materials 0.000 abstract 7
- 239000011737 fluorine Substances 0.000 abstract 7
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 6
- 150000002367 halogens Chemical group 0.000 abstract 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 5
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 5
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 4
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 abstract 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 abstract 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 abstract 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract 2
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 abstract 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000002393 azetidinyl group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- -1 cyano, hydroxy Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicacion 1: Un compuesto de la formula estructural (1) o una sal farmacéuticamente aceptable del mismo, en la que: cada n es independientemente 0, 1, 2 o 3; cada m es independientemente 0, 1 o 2: cada p es independientemente 0 o 1; V se selecciona de los restos del grupo de formulas (2); Ar es fenilo opcionalmente sustituido con de uno a cinco sustituyentes R1; cada R1 se selecciona independientemente del grupo constituido por halogeno, ciano, hidroxi, alquilo C1-6 opcionalmente sustituido con de uno a cinco átomos de fluor y alcoxi C1-6 opcionalmente sustituido con de uno a cinco átomos de fluor; cada R2 se selecciona independientemente del grupo constituido por hidrogeno; hidroxi; halogeno; ciano; alcoxi C1-10, en el que alcoxi está opcionalmente sustituido con de uno a cinco sustituyentes que se seleccionan independientemente de fluor e hidroxi; alquilo C1-10, en el que alquilo está opcionalmente sustituido con de uno a cinco sustituyentes que se seleccionan independientemente de fluor e hidroxi; alquenilo C2-10, en el que alquenilo está opcionalmente sustituido con de uno a cinco sustituyentes que se seleccionan independientemente de fluor e hidroxi; (CH2)n-arilo, en el que arilo está opcionalmente sustituido con de uno a cinco sustituyentes que se seleccionan independientemente de hidroxi, halogeno, ciano, nitro, CO2H, (alquil C1-6)oxicarbonilo, alquilo C1-6 y alcoxi C1-6, en el que alquilo y alcoxi están opcionalmente sustituidos con de uno a cinco átomos de fluor; (CH2)n-heteroarilo, en el que heteroarilo está opcionalmente sustituido con de uno a tres sustituyentes que se seleccionan independientemente de hidroxi, halogeno, ciano, nitro, CO2H, (alquil C1-6)oxicarbonilo, alquilo C1-6 y alcoxi C1-6, en el que alquilo y alcoxi están opcionalmente sustituidos con de uno a cinco átomos de fluor; (CH2)n-heterociclilo, en el que heterociclilo está opcionalmente sustituido con de uno a tres sustituyentes que se seleccionan independientemente de oxo, hidroxi, halogeno, ciano, nitro, CO2H, (alquil C1-6)oxicarbonilo, alquilo C1-6 y alcoxi C1-6, en el que alquilo y alcoxi están opcionalmente sustituidos con de uno a cinco átomos de fluor; (CH2)n-cicloalquilo C3-6, en el que cicloalquilo está opcionalmente sustituido con de uno a tres sustituyentes que se seleccionan independientemente de halogeno, hidroxi, ciano, nitro, CO2H, (alquil C1-6)oxicarbonilo, alquilo C1-6 y alcoxi C1-6, en el que alquilo y alcoxi están opcionalmente sustituidos con de uno a cinco átomos de fluor; (CH2)n-COOH; (CH2)n-COO-alquilo C1-6; (CH2)n-NR4R5; (CH2)n-CONR4R5; (CH2)n-OCONR4R5; (CH2)n-SO2NR4R5; (CH2)n-SO2R6; (CH2)n-NR7SO2R6; (CH2)n-NR7CONR4R5; (CH2)n-NR7COR7; y (CH2)n-NR7CO2R6; en los que cualquier átomo de carbono de cualquier metileno (CH2) individual de (CH2)n está opcionalmente sustituido con de uno a dos sustituyentes que se seleccionan independientemente de fluor, hidroxi, alquilo C1-4 y alcoxi C1-4, en el que alquilo y alcoxi están opcionalmente sustituidos con de uno a cinco átomos de fluor; R3a y R3b son cada uno independientemente hidrogeno o alquilo C1-4, opcionalmente sustituidos con de uno a cinco átomos de fluor; R4 y R5 se seleccionan cada uno independientemente del grupo constituido por hidrogeno, (CH2)m-fenilo, (CH2)m-cicloalquilo C3-6 y alquilo C1-6, en el que alquilo está opcionalmente sustituido con de uno a cinco sustituyentes que se seleccionan independientemente de fluor e hidroxi y en el que fenilo y cicloalquilo están opcionalmente sustituidos con de uno a cinco sustituyentes que se seleccionan independientemente de halogeno, hidroxi, alquilo C1-6 y alcoxi C1-6, en el que alquilo y alcoxi están opcionalmente sustituidos con de uno a cinco átomos de fluor; o R4 y R5 junto con el átomo de nitrogeno al que están unidos forman un anillo heterocíclico que se selecciona de azetidina, pirrolidina, piperidina, piperazina y morfolina, en los que dicho anillo heterocíclico está opcionalmente sustituido con de uno a tres sustituyentes que se seleccionan independientemente de halogeno, hidroxi, alquilo C1-6 y alcoxi C1-6, en el que alquilo y alcoxi están opcionalmente sustituidos con de uno a cinco átomos de fluor; cada R6 es independientemente alquilo C1-6, en el que alquilo está opcionalmente sustituido con de uno a cinco sustituyentes que se seleccionan independientemente de fluor e hidroxi; R7 es hidrogeno o R6; y R8 se selecciona del grupo constituido por hidrogeno, (CH2)p-fenilo, (CH2)p-cicloalquilo C3-6 y alquilo C1-6, en el que alquilo está opcionalmente sustituido con de uno a cinco sustituyentes que se seleccionan independientemente de fluor e hidroxi y en el que fenilo y cicloalquilo están opcionalmente sustituidos con de uno a cinco sustituyentes que se seleccionan independientemente de halogeno, hidroxi, alquilo C1-6 y alcoxi C1-6, en el que alquilo y alcoxi están opcionalmente sustituidos con de uno a cinco átomos de fluor.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78651806P | 2006-03-28 | 2006-03-28 | |
| US83812206P | 2006-08-16 | 2006-08-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR059984A1 true AR059984A1 (es) | 2008-05-14 |
Family
ID=38521359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070101127A AR059984A1 (es) | 2006-03-28 | 2007-03-20 | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa -iv para el tratamiento o prevencion de diabetes |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US7678905B2 (es) |
| EP (1) | EP2001883B1 (es) |
| JP (1) | JP5229706B2 (es) |
| KR (1) | KR20090005306A (es) |
| AR (1) | AR059984A1 (es) |
| AT (1) | ATE554091T1 (es) |
| AU (1) | AU2007243631B2 (es) |
| BR (1) | BRPI0709141A2 (es) |
| CA (1) | CA2646962C (es) |
| CR (1) | CR10343A (es) |
| DO (1) | DOP2007000051A (es) |
| EA (1) | EA200870380A1 (es) |
| EC (1) | ECSP088765A (es) |
| GT (1) | GT200800184A (es) |
| MA (1) | MA30333B1 (es) |
| MX (1) | MX2008012490A (es) |
| NO (1) | NO20084508L (es) |
| PE (1) | PE20071104A1 (es) |
| SV (1) | SV2008003045A (es) |
| TN (1) | TNSN08367A1 (es) |
| TW (1) | TW200806669A (es) |
| WO (1) | WO2007126745A2 (es) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007218053B2 (en) | 2006-02-15 | 2010-05-27 | Merck Sharp & Dohme Corp. | Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
| EP2019677B1 (en) | 2006-05-16 | 2013-08-14 | Merck Sharp & Dohme Corp. | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| JP5232160B2 (ja) | 2006-11-14 | 2013-07-10 | メルク・シャープ・アンド・ドーム・コーポレーション | 糖尿病の治療又は予防のためのジペプチジルペプチダーゼｉｖインヒビターとしての三環式芳香族複素環化合物 |
| WO2009014676A1 (en) * | 2007-07-23 | 2009-01-29 | Merck & Co., Inc. | Novel crystalline form of a dihydrochloride salt of a dipeptidyl peptidase-iv inhibitor |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| CA2696211C (en) | 2007-08-21 | 2015-05-26 | Merck Sharp & Dohme Corp. | Heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| US7902376B2 (en) | 2008-01-23 | 2011-03-08 | Merck Sharp & Dohme Corp. | Process for preparing chiral dipeptidyl peptidase-IV inhibitor intermediates |
| JO2870B1 (en) | 2008-11-13 | 2015-03-15 | ميرك شارب اند دوهم كورب | Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes |
| BR112012004335A8 (pt) * | 2009-09-02 | 2016-06-21 | Merck Sharp & Dohme | Composto, composição farmacêutica, e, uso do composto. |
| CA2772188A1 (en) * | 2009-09-23 | 2011-03-31 | Pfizer Inc. | Gpr 119 modulators |
| EP2480082A4 (en) | 2009-09-25 | 2014-01-15 | Merck Sharp & Dohme | SUBSTITUTED AMINOPIPERIDINES AS DIPEPTIDYLPEPTIDASE IV INHIBITORS FOR THE TREATMENT OF DIABETES |
| WO2011103256A1 (en) | 2010-02-22 | 2011-08-25 | Merck Sharp & Dohme Corp. | Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2011146358A1 (en) | 2010-05-21 | 2011-11-24 | Merck Sharp & Dohme Corp. | Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| US8691832B2 (en) | 2010-12-06 | 2014-04-08 | Merck Sharp & Dohme Corp. | Tricyclic heterocycles useful as dipeptidyl peptidase-IV inhibitors |
| EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2683700B1 (de) | 2011-03-08 | 2015-02-18 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| CN103987388A (zh) | 2011-06-29 | 2014-08-13 | 默沙东公司 | 二肽基肽酶-iv抑制剂的新晶形 |
| US9051329B2 (en) | 2011-07-05 | 2015-06-09 | Merck Sharp & Dohme Corp. | Tricyclic heterocycles useful as dipeptidyl peptidase-IV inhibitors |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013122920A1 (en) | 2012-02-17 | 2013-08-22 | Merck Sharp & Dohme Corp. | Dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| EP2874622A4 (en) | 2012-07-23 | 2015-12-30 | Merck Sharp & Dohme | TREATMENT OF DIABETES WITH DIPEPTIDYLPEPTIDASE IV INHIBITORS |
| WO2014018355A1 (en) * | 2012-07-23 | 2014-01-30 | Merck Sharp & Dohme Corp. | Treating diabetes with dipeptidyl peptidase-iv inhibitors |
| TWI500613B (zh) * | 2012-10-17 | 2015-09-21 | Cadila Healthcare Ltd | 新穎之雜環化合物 |
| CN105142621A (zh) | 2012-10-24 | 2015-12-09 | 国家健康科学研究所 | 用于预防或治疗糖尿病和促进β-细胞存活的TPL2激酶抑制剂 |
| CN105085528A (zh) * | 2014-05-15 | 2015-11-25 | 成都贝斯凯瑞生物科技有限公司 | 作为二肽基肽酶-iv抑制剂的氨基四氢吡喃衍生物 |
| MY181641A (en) * | 2014-06-17 | 2020-12-30 | Sichuan Haisco Pharmaceutical Co Ltd | Amino pyran ring derivative and composition and use thereof |
| WO2016014324A1 (en) | 2014-07-21 | 2016-01-28 | Merck Sharp & Dohme Corp. | Process for preparing chiral dipeptidyl peptidase-iv inhibitors |
| RU2702644C2 (ru) * | 2014-10-31 | 2019-10-09 | Ист Чайна Юниверсити Оф Сайенс Энд Текнолоджи | Бензопроизводные с шестичленным кольцом в качестве ингибитора dpp-4 и их применение |
| CN105985357A (zh) * | 2015-02-12 | 2016-10-05 | 北京赛林泰医药技术有限公司 | 取代的氨基六元饱和杂脂环类长效dpp-iv抑制剂 |
| WO2016151018A1 (en) | 2015-03-24 | 2016-09-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method and pharmaceutical composition for use in the treatment of diabetes |
| US10377732B2 (en) | 2015-12-03 | 2019-08-13 | F.I.S.—Fabbrica Italiana Sintetici S.p.A. | Process for preparing aminotetrahydropyrans |
| WO2017202357A1 (zh) * | 2016-05-25 | 2017-11-30 | 四川海思科制药有限公司 | 一种三氟甲基取代的吡喃衍生物的制备方法 |
| WO2017202365A1 (zh) * | 2016-05-25 | 2017-11-30 | 四川海思科制药有限公司 | 一种三氟甲基取代的吡喃衍生物制备方法 |
| AR111295A1 (es) | 2017-03-20 | 2019-06-26 | Forma Therapeutics Inc | Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr) |
| WO2020061255A1 (en) | 2018-09-19 | 2020-03-26 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
| US20200129485A1 (en) | 2018-09-19 | 2020-04-30 | Forma Therapeutics, Inc. | Treating sickle cell disease with a pyruvate kinase r activating compound |
| RS67259B1 (sr) | 2019-09-19 | 2025-10-31 | Novo Nordisk Healthcare Ag | Kompozicije koje aktiviraju piruvat kinazu r (pkr) |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5114961A (en) * | 1989-06-08 | 1992-05-19 | Merck & Co., Inc. | 2,5-diaryl tetrahydrofurans and analogs thereof as PAF antagonists |
| WO2003002553A2 (en) * | 2001-06-27 | 2003-01-09 | Smithkline Beecham Corporation | Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
| JP2007513058A (ja) * | 2003-09-08 | 2007-05-24 | 武田薬品工業株式会社 | ジペプチジルぺプチダーゼ阻害剤 |
| EP1761532B1 (en) * | 2004-06-21 | 2013-04-10 | Merck Sharp & Dohme Corp. | Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| ATE481969T1 (de) | 2004-10-01 | 2010-10-15 | Merck Sharp & Dohme | Aminopiperidine als dipeptidylpeptidase-iv- inhibitoren zur behandlung oder prävention von diabetes |
| JP4999698B2 (ja) | 2004-11-29 | 2012-08-15 | メルク・シャープ・エンド・ドーム・コーポレイション | 糖尿病の治療または予防用のジペプチジルペプチダーゼ−ｉｖ阻害剤としての縮合アミノピペリジン |
| EP1888066B1 (en) | 2005-05-25 | 2012-01-11 | Merck Sharp & Dohme Corp. | Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| ATE549926T1 (de) | 2005-08-26 | 2012-04-15 | Merck Sharp & Dohme | Kondensierte aminopiperidine als dipeptidylpeptidase-iv-inhibitoren zur behandlung oder prävention von diabetes |
| AU2007218053B2 (en) * | 2006-02-15 | 2010-05-27 | Merck Sharp & Dohme Corp. | Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
| EP2019677B1 (en) * | 2006-05-16 | 2013-08-14 | Merck Sharp & Dohme Corp. | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| JP5232160B2 (ja) * | 2006-11-14 | 2013-07-10 | メルク・シャープ・アンド・ドーム・コーポレーション | 糖尿病の治療又は予防のためのジペプチジルペプチダーゼｉｖインヒビターとしての三環式芳香族複素環化合物 |
-
2007
- 2007-03-19 TW TW096109375A patent/TW200806669A/zh unknown
- 2007-03-20 AR ARP070101127A patent/AR059984A1/es not_active Application Discontinuation
- 2007-03-20 DO DO2007000051A patent/DOP2007000051A/es unknown
- 2007-03-23 PE PE2007000315A patent/PE20071104A1/es not_active Application Discontinuation
- 2007-03-26 EA EA200870380A patent/EA200870380A1/ru unknown
- 2007-03-26 KR KR1020087023571A patent/KR20090005306A/ko not_active Withdrawn
- 2007-03-26 EP EP07754011A patent/EP2001883B1/en active Active
- 2007-03-26 AU AU2007243631A patent/AU2007243631B2/en not_active Ceased
- 2007-03-26 MX MX2008012490A patent/MX2008012490A/es unknown
- 2007-03-26 AT AT07754011T patent/ATE554091T1/de active
- 2007-03-26 WO PCT/US2007/007434 patent/WO2007126745A2/en not_active Ceased
- 2007-03-26 JP JP2009502918A patent/JP5229706B2/ja not_active Expired - Fee Related
- 2007-03-26 BR BRPI0709141-9A patent/BRPI0709141A2/pt not_active IP Right Cessation
- 2007-03-26 CA CA2646962A patent/CA2646962C/en not_active Expired - Fee Related
- 2007-03-27 US US11/728,673 patent/US7678905B2/en active Active
-
2008
- 2008-09-17 GT GT200800184A patent/GT200800184A/es unknown
- 2008-09-22 TN TNP2008000367A patent/TNSN08367A1/en unknown
- 2008-09-24 EC EC2008008765A patent/ECSP088765A/es unknown
- 2008-09-26 SV SV2008003045A patent/SV2008003045A/es not_active Application Discontinuation
- 2008-10-06 CR CR10343A patent/CR10343A/es unknown
- 2008-10-14 MA MA31288A patent/MA30333B1/fr unknown
- 2008-10-27 NO NO20084508A patent/NO20084508L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0709141A2 (pt) | 2011-06-28 |
| JP5229706B2 (ja) | 2013-07-03 |
| WO2007126745A3 (en) | 2007-12-21 |
| EP2001883A2 (en) | 2008-12-17 |
| TW200806669A (en) | 2008-02-01 |
| ATE554091T1 (de) | 2012-05-15 |
| KR20090005306A (ko) | 2009-01-13 |
| EA200870380A1 (ru) | 2009-02-27 |
| AU2007243631B2 (en) | 2011-11-24 |
| MX2008012490A (es) | 2008-10-10 |
| EP2001883B1 (en) | 2012-04-18 |
| SV2008003045A (es) | 2009-11-09 |
| NO20084508L (no) | 2008-10-27 |
| JP2009531437A (ja) | 2009-09-03 |
| GT200800184A (es) | 2011-09-05 |
| MA30333B1 (fr) | 2009-04-01 |
| WO2007126745A2 (en) | 2007-11-08 |
| US7678905B2 (en) | 2010-03-16 |
| DOP2007000051A (es) | 2007-12-15 |
| ECSP088765A (es) | 2008-10-31 |
| CR10343A (es) | 2008-10-29 |
| CA2646962C (en) | 2011-06-21 |
| PE20071104A1 (es) | 2007-12-29 |
| TNSN08367A1 (en) | 2009-12-29 |
| US20070232676A1 (en) | 2007-10-04 |
| CA2646962A1 (en) | 2007-11-08 |
| AU2007243631A1 (en) | 2007-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR059984A1 (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa -iv para el tratamiento o prevencion de diabetes | |
| AR074306A1 (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes | |
| PE20071009A1 (es) | Compuestos derivados de fenoxipiperidinas como antagonistas de histamina h3 | |
| AR040626A1 (es) | Derivados de quinolina utiles como ligandos del receptor del neuropeptido y (npy) | |
| AR084849A1 (es) | Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| AR075729A1 (es) | Derivados de benzofuranilo, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la obesidad y/o diabetes. | |
| EA201390717A1 (ru) | 3-(аминоарил)пиридиновые соединения | |
| AR073348A1 (es) | Inhibidores ciclicos de 11 beta-hidroxiesteroide deshidrogenasa 1 | |
| AR070274A1 (es) | Derivados arilamida diazepinopirimidona sustituidos utiles en el tratamiento y/o prevencion de enfermedades neurodegenerativas y otras, provocadas por la actividad anormal de quinasas gsk3beta, medicamentos que los contienen y proceso de preparacion e intermediarios. | |
| PE20061150A1 (es) | Derivados de n-(n-sulfonilaminoarilmetil)ciclopropanocarboxamida sustituidos como antagonistas del receptor vainilloide tipo 1 (vdr1) | |
| AR076008A1 (es) | Derivados de hidroximetil-isoxazol moduladores de receptores gaba a, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento del alzheimer y otros trastornos cognitivos. | |
| AR081058A1 (es) | Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer. | |
| AR068376A1 (es) | Amidas heterociclicas utiles para inhibir la via hedgehog. | |
| PE20141075A1 (es) | 4-aril-n-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina | |
| CO6612267A2 (es) | Nuevos derivados de 1,1 dióxido- 5 fenil- 2,3,4-5tetrahidro- 1,4-benzotiazepina y composiciones farmaceúticas que los comprenden | |
| CA2582447A1 (en) | Aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR072227A1 (es) | Derivados de triazinona sustituidos | |
| AR067327A1 (es) | Derivados de piperidina / piperazina | |
| AR066153A1 (es) | Derivados de piperidina / piperazina | |
| ES2662444T3 (es) | Derivado de piridina | |
| AR057989A1 (es) | Derivados de indol-2-il-amida 1,5-sustituida. procesos de obtencion y composiciones farmaceuticas | |
| RU2008142600A (ru) | Органическое соединение | |
| AR072793A1 (es) | Compuestos de aril isoxazol con actividades antitumorales |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |